Consort Medical plc (“Consort Medical”, “Consort”) (LSE: CSRT), is pleased to announce the successful signing of a significant new commercial supply agreement for Bespak’s proprietary respiratory devices.
AstraZeneca AB (“AstraZeneca”) and Bespak have agreed to enter into a multi-year agreement for the scale-up and supply of Bespak’s proprietary pressurised metered dose inhaler (pMDI) valves and actuators. These components will be assembled with AstraZeneca’s Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. AstraZeneca announced that its device was approved by the US Food and Drug Administration on 25 April 2016.
These products will be manufactured in Bespak’s existing King’s Lynn facility. Going forwards the project will be referred to as VAL100.
Jon Glenn, Chief Executive Officer of Consort Medical, commented: “We are delighted to have successfully concluded this agreement with AstraZeneca. This further reinforces the ongoing strength of our respiratory device franchise in the pMDI segment.”
